UCB and Sepracor sue Synthon over levocetirizine solution ANDA
This article was originally published in Scrip
Executive Summary
UCB and Sepracor have filed suit in the US District Court for the Eastern District of North Carolina against Synthon Pharmaceuticals, alleging patent infringement related to its generic version of Xyzal solution 2.5mg/5ml, thus triggering a 30-month stay of approval.